乳腺富糖原透明细胞癌的临床病理分析并文献复习  

Clinicophthologic characteristics of glycogen-rich clear cell carcinoma of the breast and review the related literature

作　　者：韩旭[1] 张钢龄 李慧[1] 张培礼[1] 冯立文[2] 

机构地区：[1]包头市肿瘤医院乳腺外科,内蒙古包头014000 [2]包头市肿瘤医院病理科,内蒙古包头014000

出　　处：《现代肿瘤医学》2017年第19期3085-3088,共4页Journal of Modern Oncology

摘　　要：目的:探讨乳腺富糖原透明细胞癌的临床病理特点及预后。方法:回顾性分析包头市肿瘤医院2008年5月至2011年5月收治的乳腺富糖原透明细胞癌患者的临床及病理资料,探讨影响预后的因素并寻找其免疫组化特点。结果:9例患者均为女性,年龄43~75岁,肿物直径15~50 mm。免疫组织化学染色结果:雌激素受体(ER)阳性率为55.56%(5/9),孕激素受体(PR)阳性率为44.44%(4/9),HER2阳性率为22.22%(2/9)。随访60个月,1例患者于术后13月发现胸壁转移、双肺转移、锁骨上淋巴结转移,并发上腔静脉综合征,于发病后19月死亡。结论:乳腺富糖原透明细胞癌与乳腺非特殊类型浸润性癌在ER表达、PR表达及HER2表达等方面比较均无显著差异,乳腺富糖原透明细胞癌预后与其组织学特性无关,而与其组织学分级、淋巴结状况和肿瘤分期有关,综合分析相关文献目前支持其治疗原则应与乳腺非特殊类型浸润性癌相同。Objective： To study the clinicopathologic fearures and prognosis of glycogen -rich clear cell carcino- ma of the breast. Methods：The data of 9 breast GRCC patients were admitted from May 2008 to May 2011 in Baotou Cancer Hospital. Their clinicopathologic data, treatment, and prognosis were retrospectively analyzed. ER or PR status and overexpression of HER2/neu protein were compared with non special invasice ductal carcinoma of the breast. Resuits：All of the 9 patients were females,aged 43 years to 75 years （mean of 55 years） ,tumor size ranged from 15 to 50 ram. 3 cases of clinical III phase accounted for 33.3%. Immunohistochemical stains results：5 cases were positive for ER,4 for PR,2 for HER2. All patients were followed up for 60 months with one dying of systemic multiple metasta- ses. Conclusion：ER, PR and HER2/neu status didn＇t appear to be markedly different from that of the usual invasive duetal carcinomas. The prognosis of glycogen - rich clear cell cancer of the breast was significantly related with histo- logical grade, the number of positive lymph nodes and clinial phase. So we support that they have the same treatment principles through the comprehensive related literature. Survieal in patients with glycogen - rich clear cell carcinoma of the breast might not be so bad.

关 键 词：乳腺肿瘤 富糖原透明细胞癌 预后 

分 类 号：R737.9[医药卫生—肿瘤]